Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression

Hyun Jung Kim, Aeree Kim, Hyeong Sik Ahn, Il Min Ahn, Jinhyuk Choi, Hyeyoon Chang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prognostic value of ErbB3 in human breast cancer is still controversial. However, the roles of ErbB3 receptors in drug resistance are recently emerging. The objective of this study was to evaluate the relationship between ErbB3 expression and survival of breast cancer via meta-analysis. A systematic literature search was conducted and 32 potentially relevant studies were included in the meta-analysis. Outcomes presented in searched literatures can be classified as disease free survival (DFS), overall survival (OS), and progress free survival (PFS) values. Meta-analysis was performed for each group. Results showed no statistically significant difference in survival. The overall hazard ratio of PFS, DFS, and OS of ErbB3 expression was 1.40 [95% confidence interval/CI (0.51, 3.83)], 1.07 [95% CI (0.82, 1.40)], and 1.15 [95% CI (0.91, 1.44)], respectively. Subgroup analysis according to ErbB2 receptor status, ErbB3 assessment methods (immunohistochemistry/IHC vs non-IHC), and analysis type (multivariate and univariate analysis) were performed. No significant association was found. Using various assessment methods and patient populations, our results revealed that there was no significant correlation between ErbB3 expression and breast cancer survival. Further studies on heterodimers of ErbB3 and other molecular markers involved in ErbB3 related pathway are merited.

Original languageEnglish
Pages (from-to)383-393
Number of pages11
JournalAPMIS
Volume123
Issue number5
DOIs
Publication statusPublished - 2015 May 1

Fingerprint

Meta-Analysis
Breast Neoplasms
Survival
Disease-Free Survival
Drug Resistance
Multivariate Analysis
Immunohistochemistry
Confidence Intervals
Population

Keywords

  • Breast cancer
  • ErbB3
  • Meta-analysis
  • Prognosis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Microbiology (medical)
  • Immunology and Allergy

Cite this

Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression. / Kim, Hyun Jung; Kim, Aeree; Ahn, Hyeong Sik; Ahn, Il Min; Choi, Jinhyuk; Chang, Hyeyoon.

In: APMIS, Vol. 123, No. 5, 01.05.2015, p. 383-393.

Research output: Contribution to journalArticle

Kim, Hyun Jung ; Kim, Aeree ; Ahn, Hyeong Sik ; Ahn, Il Min ; Choi, Jinhyuk ; Chang, Hyeyoon. / Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression. In: APMIS. 2015 ; Vol. 123, No. 5. pp. 383-393.
@article{c0de5af1dea741d895be3030c56f661e,
title = "Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression",
abstract = "Prognostic value of ErbB3 in human breast cancer is still controversial. However, the roles of ErbB3 receptors in drug resistance are recently emerging. The objective of this study was to evaluate the relationship between ErbB3 expression and survival of breast cancer via meta-analysis. A systematic literature search was conducted and 32 potentially relevant studies were included in the meta-analysis. Outcomes presented in searched literatures can be classified as disease free survival (DFS), overall survival (OS), and progress free survival (PFS) values. Meta-analysis was performed for each group. Results showed no statistically significant difference in survival. The overall hazard ratio of PFS, DFS, and OS of ErbB3 expression was 1.40 [95{\%} confidence interval/CI (0.51, 3.83)], 1.07 [95{\%} CI (0.82, 1.40)], and 1.15 [95{\%} CI (0.91, 1.44)], respectively. Subgroup analysis according to ErbB2 receptor status, ErbB3 assessment methods (immunohistochemistry/IHC vs non-IHC), and analysis type (multivariate and univariate analysis) were performed. No significant association was found. Using various assessment methods and patient populations, our results revealed that there was no significant correlation between ErbB3 expression and breast cancer survival. Further studies on heterodimers of ErbB3 and other molecular markers involved in ErbB3 related pathway are merited.",
keywords = "Breast cancer, ErbB3, Meta-analysis, Prognosis",
author = "Kim, {Hyun Jung} and Aeree Kim and Ahn, {Hyeong Sik} and Ahn, {Il Min} and Jinhyuk Choi and Hyeyoon Chang",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/apm.12371",
language = "English",
volume = "123",
pages = "383--393",
journal = "Acta pathologica et microbiologica Scandinavica",
issn = "0365-5555",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression

AU - Kim, Hyun Jung

AU - Kim, Aeree

AU - Ahn, Hyeong Sik

AU - Ahn, Il Min

AU - Choi, Jinhyuk

AU - Chang, Hyeyoon

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Prognostic value of ErbB3 in human breast cancer is still controversial. However, the roles of ErbB3 receptors in drug resistance are recently emerging. The objective of this study was to evaluate the relationship between ErbB3 expression and survival of breast cancer via meta-analysis. A systematic literature search was conducted and 32 potentially relevant studies were included in the meta-analysis. Outcomes presented in searched literatures can be classified as disease free survival (DFS), overall survival (OS), and progress free survival (PFS) values. Meta-analysis was performed for each group. Results showed no statistically significant difference in survival. The overall hazard ratio of PFS, DFS, and OS of ErbB3 expression was 1.40 [95% confidence interval/CI (0.51, 3.83)], 1.07 [95% CI (0.82, 1.40)], and 1.15 [95% CI (0.91, 1.44)], respectively. Subgroup analysis according to ErbB2 receptor status, ErbB3 assessment methods (immunohistochemistry/IHC vs non-IHC), and analysis type (multivariate and univariate analysis) were performed. No significant association was found. Using various assessment methods and patient populations, our results revealed that there was no significant correlation between ErbB3 expression and breast cancer survival. Further studies on heterodimers of ErbB3 and other molecular markers involved in ErbB3 related pathway are merited.

AB - Prognostic value of ErbB3 in human breast cancer is still controversial. However, the roles of ErbB3 receptors in drug resistance are recently emerging. The objective of this study was to evaluate the relationship between ErbB3 expression and survival of breast cancer via meta-analysis. A systematic literature search was conducted and 32 potentially relevant studies were included in the meta-analysis. Outcomes presented in searched literatures can be classified as disease free survival (DFS), overall survival (OS), and progress free survival (PFS) values. Meta-analysis was performed for each group. Results showed no statistically significant difference in survival. The overall hazard ratio of PFS, DFS, and OS of ErbB3 expression was 1.40 [95% confidence interval/CI (0.51, 3.83)], 1.07 [95% CI (0.82, 1.40)], and 1.15 [95% CI (0.91, 1.44)], respectively. Subgroup analysis according to ErbB2 receptor status, ErbB3 assessment methods (immunohistochemistry/IHC vs non-IHC), and analysis type (multivariate and univariate analysis) were performed. No significant association was found. Using various assessment methods and patient populations, our results revealed that there was no significant correlation between ErbB3 expression and breast cancer survival. Further studies on heterodimers of ErbB3 and other molecular markers involved in ErbB3 related pathway are merited.

KW - Breast cancer

KW - ErbB3

KW - Meta-analysis

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84928226460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928226460&partnerID=8YFLogxK

U2 - 10.1111/apm.12371

DO - 10.1111/apm.12371

M3 - Article

VL - 123

SP - 383

EP - 393

JO - Acta pathologica et microbiologica Scandinavica

JF - Acta pathologica et microbiologica Scandinavica

SN - 0365-5555

IS - 5

ER -